VRTX

Vertex Pharmaceuticals Incorporated (VRTX)

Last Price$409.9(0.5%)
Market Cap$105.0B
Intrinsic value score
6/10
Good
Intrinsic value
$354.5
DCF value - $493.3 Relative value - $215.8
Overvalued
13.5%
LTM P/E
(218.8x)
Peer set median 6.4x
Discount rate
7.9%

VRTX Intrinsic value

Crunching data... Almost there!

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

VRTX Historical Intrinsic Value

Crunching data... Almost there!

VRTX vs Peer Set: Intrinsic Value Comparison

Crunching data... Almost there!

Explore more intrinsic value tools hub for VRTX

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

What is Vertex Pharmaceuticals Incorporated intrinsic value?

As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated Intrinsic Value is $354.5. This suggests it may be overvalued by 13.5% compared to its current price of around $409.9.

What is Vertex Pharmaceuticals Incorporated DCF (discounted cash flow) valuation?

As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at $499.0. This suggests it may be overvalued by 21.7% to its current price of around $409.9, using a discount rate of 7.9% and terminal growth rate of 3.0%.

Is Vertex Pharmaceuticals Incorporated overvalued or undervalued?

Vertex Pharmaceuticals Incorporated is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $354.5, compared to a market price of around $409.9. This suggests a potential overvaluation of 13.5%.